1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Austria >
  5. DSM-Firmenich Acquires Erber AG

M&A Deal Summary

DSM-Firmenich Acquires Erber AG

On June 12, 2020, DSM-Firmenich acquired life science company Erber AG for 980M EUR

Acquisition Highlights
  • This is DSM-Firmenich’s 9th transaction in the Life Science sector.
  • This is DSM-Firmenich’s 2nd largest (disclosed) transaction.
  • This is DSM-Firmenich’s 1st transaction in Austria.

M&A Deal Summary
Date 2020-06-12
Target Erber AG
Sector Life Science
Buyer(s) DSM-Firmenich
Deal Type Add-on Acquisition
Deal Value 980M EUR

Target

Erber AG

Getzersdorf, Austria
Erber AG is involved in the field of food and feed safety, focusing on natural feed additives, feed, and food analysis and plant protection with headquarters in Austria/Getzersdorf. Erber consists of BIOMIN, ROMER LABS, SANPHAR, and EFB. Including distribution partners, Erber is represented in more than 140 countries worldwide. The international orientation and in-house research and development are important success factors for the annual growth. Erber was formed in 1983 and is based in Getzersdorf, Austria.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

DSM-Firmenich

Kaiseraugst, Switzerland
Category Company
Founded 1902
Sector Chemicals
Employees26,301
Revenue 12.8B EUR (2024)
DESCRIPTION

DSM-Firmenich specializes in the development, manufacture, and marketing of performance materials, nutritional and pharmaceutical ingredients, and industrial chemicals. The products are used in a wide range of end-markets and applications, such as human and animal nutrition and health, personal care, pharmaceuticals, automotive and transport, coatings and paint, housing, and electrics & electronics. DSM-Firmenich was founded in 1902 and is based in Kaiseraugst, Switzerland.

DEAL STATS #
Overall 27 of 28
Sector: Life Science M&A 9 of 9
Type: Add-on Acquisition M&A Deals 19 of 19
Country: Austria M&A 1 of 1
Year: 2020 M&A 1 of 1
Size (of disclosed) 2 of 13
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-19 Koninklijke DSM N.V. - BIO 300

Swaziland

Koninklijke DSM N.V. (Royal DSM) - BIO 300 is a clinical-stage drug under development to protect normal tissues from the harm caused by radiation. The drug’s radioprotective effects were originally discovered by researchers within the Department of Defense at the Armed Forces Radiobiology Research Institute.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-04-20 DSM - Protective Materials Business

Heerlen, Netherlands

DSM's Protective Materials Business provides the development of ultra-strong bio-based and circular materials.

Sell €1.4B
Mergr

Solution for

Product

Company

Legal